Gonzalez J A, Marcol B R, Wolf M C
Department of Urology, William Beaumont Hospital, Royal Oak, Michigan.
J Urol. 1992 Dec;148(6):1892-3. doi: 10.1016/s0022-5347(17)37062-3.
Bacillus Calmette-Guerin (BCG) is the most effective agent currently available to treat superficial bladder cancer. However, this form of therapy is not without potential serious or fatal complications. In addition to the potentially toxic systemic side effects attributed to hematogenous absorption of the bacillus, direct upper tract seeding may occur in patients with vesicoureteral reflux. We report on a patient treated with intravesical BCG for bladder cancer in whom unilateral necrotizing granulomatous pyelonephritis developed. Although severe, this complication is rare and we conclude that reflux is not a contraindication for intravesical BCG therapy.
卡介苗（BCG）是目前可用于治疗浅表性膀胱癌的最有效药物。然而，这种治疗方式并非没有潜在的严重或致命并发症。除了因杆菌血行吸收导致的潜在毒性全身副作用外，膀胱输尿管反流患者可能会发生上尿路直接播散。我们报告了一名接受膀胱内卡介苗治疗膀胱癌的患者，该患者发生了单侧坏死性肉芽肿性肾盂肾炎。尽管这种并发症很严重，但很罕见，我们得出结论，反流并非膀胱内卡介苗治疗的禁忌证。
